A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 1068-1073

  Creary, Susan E ^a   Gladwin, Mark T ^b   Byrne, Melissa ^c   Hildesheim, Mariana ^b   Krishnamurti, Lakshmanan ^c  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Hydroxyurea; Medication adherence; Sickle cell

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER; DIRECTLY OBSERVED THERAPY; DRUG DOSE ESCALATION; FEMALE; HEALTH CARE SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; MOBILE PHONE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILOT STUDY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

HYDROXYUREA; MEDICATION ADHERENCE; SICKLE CELL;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CELLULAR PHONE; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; ELECTRONIC MAIL; FEEDBACK; FEMALE; HEALTH SURVEYS; HUMANS; HYDROXYUREA; MALE; MEDICATION ADHERENCE; MICROCOMPUTERS; PATIENT SATISFACTION; PILOT PROJECTS; REIMBURSEMENT, INCENTIVE; REMINDER SYSTEMS; REWARD; TEXT MESSAGING; VIDEO RECORDING; YOUNG ADULT;

EID: 84901699731     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24931     Document Type: Article

References (28)

1. National Heart, Lung, and Blood Institute, Disease and Conditions Index: Sickle cell anemia: Who is at risk? http://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk.html (Accessed August 7, 2012).
2. Platt O, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Eng J Med 1994; 330:1639-1644.
3. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007; 48:705-710.
4. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111:231-239.
5. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005; 106:2269-2275.
6. Paule I, Sassi H, Habibi A, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis 2011; 6:30.
7. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality, morbidity in adult sickle cell anemia: Risks, benefits up to 9 years of treatment. JAMA 2003; 289:1645-1651.
8. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663-1672.
9. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86:273-277.
10. Thornburg CD, Rogers ZR, Jeng MR, et al. Adherence to study medication and visits: Data from the BABY HUG trial. Pediatr Blood Cancer 2010; 54:260-264.
11. Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 2010; 156:415-419.
12. Lanzkron S, Haywood C, Fagan PJ, et al. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved 2010; 21:277-286.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
14. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-1322.
15. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-1184.
16. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med 1993; 328:576-578.
17. Shin S, Muñoz M, Zeladita J, et al. How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community 2011; 19:261-271.
18. Berg KM, Litwin AH, Li X, et al. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention. Clin Infect Dis 2011; 53:936-943.
19. Horrigan J. Wireless internet use. http://pewinternet.org/Reports/2009/12-Wireless-Internet-Use.aspx (Accessed August 5, 2012).
20. Smith A. Mobile access. 2010; http://pewinternet.org/Reports/2010/Mobile-Access-2010.aspx (Accessed August 5, 2012).
21. Hensel BK, Demiris G, Courtney KL. Defining obtrusiveness in home telehealth technologies: A conceptual framework. J Am Med Inform Assoc 2006; 13:428-431.
22. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care 1986; 24:67-74.
23. Morisky DE, Malotte CK, Choi P, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q 1990; 17:253-267.
24. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: Response to authors. J Clin Epidemiol 2011; 64:255-257.
25. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15:565-577.
26. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002; 99:10-14.
27. Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 2009; 7:36.
28. Volpp KG, Asch DA, Galvin R, et al. Redesigning employee health incentives-Lessons from behavioral economics. N Engl J Med 2011; 365:388-390.